Abstract
Herein, we report the synthesis and structure-activity relationship studies of new analogs of boceprevir 1 and telaprevir 2. Introduction of azetidine and spiroazetidines as a P2 substituent that replaced the pyrrolidine moiety of 1 and 2 led to the discovery of a potent hepatitis C protease inhibitor 37c (EC50=0.8 μM).
Keywords:
Antiviral; HCV; Protease inhibitor.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Antiviral Agents / chemical synthesis
-
Antiviral Agents / chemistry
-
Antiviral Agents / pharmacology*
-
Azetidines / chemistry*
-
Azetidines / pharmacology*
-
Drug Design
-
Hepatitis C / drug therapy*
-
Humans
-
Models, Molecular
-
Protease Inhibitors / chemical synthesis
-
Protease Inhibitors / chemistry
-
Protease Inhibitors / pharmacology*
-
Structure-Activity Relationship
-
Viral Nonstructural Proteins / antagonists & inhibitors*
-
Viral Nonstructural Proteins / chemistry*
Substances
-
Antiviral Agents
-
Azetidines
-
NS3 protein, hepatitis C virus
-
Protease Inhibitors
-
Viral Nonstructural Proteins